Age-Related Macular Degeneration Therapeutics Pipeline Analysis Analysis by Trends, Size, Share, Growth Opportunities, and Emerging Technologies Age-related macular degeneration (AMD) is a progressive eye condition that impacts millions of individuals globally, mainly those aged 50 and more. It is one of the leading causes of vision loss and blindness, significantly impacting the quality of life for individuals. Over the years, extensive R&D efforts have been dedicated to finding effective therapeutics for AMD. In this article, we will explore the promising pipeline of treatments for AMD. Current Status of Wet AMD Medications Also known as advanced neovascular AMD, this eye illness is not that common, and it develops at a faster pace in comparison to dry AMD. However, even dry AMD can also turn into wet AMD. It occurs when abnormal blood vessels form in the back of the eye and harm the macula. But, the only good thing about wet AMD is that the cure for this illness is available. These days, only a limited number of medications to cure this illness are licensed, the most prominent of them being anti-VEGF agents. Such medicines require regular and uncomfortable intraocular injections, which stop the formation of this molecule, thus effectively stopping the formation of the excess blood vessels that damage vision. Browse detailed report - https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-therapeutics-pipeline-analysis How Can You Lower Risk for AMD? According to research, you can be able to lower your risk of AMD (or slow vision loss from AMD) by following these healthy choices: • Don’t smoke • Regular physical exercise • Keep blood pressure and cholesterol in check • Eat healthy foods, such as leafy green vegetables and fish Hence, even though the therapeutics pipeline for age-related macular degeneration, particularly wet AMD, is quite promising, a healthy lifestyle can help you avoid this illness altogether.